Subspecies: subsp. schtitka (HMT-0106) Primary Body Site: Oral
Download Options
Hide Legend
Prev - Prevalence
10thp - 10th percentile
90thp - 90th percentile
ND - less than 0.001%
Body Site Legend:
| SUBP-- Subgingival Plaque |
| SUPP -- Supragingival Plaque |
| PERIO -- Periodontal |
| AKE -- Attached Keratinized Gingiva |
| BMU -- Buccal Mucosa |
| HPA -- Hard Palate |
| SAL -- Saliva |
| THR -- Throat |
| PTO -- Palatine Tonsils |
| TDO -- Tongue Dorsum |
| ANA -- Anterior Nares |
| LRC -- L_Retroauricular Crease |
| RRC -- R_Retroauricular Crease |
| LAF -- L_Antecubital Fossa |
| RAF -- R_Antecubital Fossa |
| VIN -- Vaginal Introitus |
| MVA -- Mid Vagina |
| PFO -- Posterior Fornix |
| STO -- Stool |
Prev - Prevalence
10thp - 10th percentile
90thp - 90th percentile
ND - less than 0.001%
Human Microbiome Project Mapping (Data from healthy subjects. - not published)
No Notes
Eren V1-V3 www.pnas.org
(Data from healthy subjects.)
No Notes
Eren V3-V5 www.pnas.org
(Data from healthy subjects.)
Notes:
Reads equally close to HMT 106 and 377 were assigned half to each taxon.
Reads equally close to HMT 081, 106, and 377 were assigned one-third to each taxon.
Reads equally close to HMT 106 and 377 were assigned half to each taxon.
Reads equally close to HMT 081, 106, and 377 were assigned one-third to each taxon.
| SUBP | SUPP | AKE | BMU | HPA | SAL | THR | PTO | TDO | STO | |
| Avg (%) | 0.14 | 0.11 | 0 | 0.01 | 0.03 | 0.07 | 0.03 | 0.03 | 0.02 | 0 |
| n | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 10thp | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 90thp | 0.37 | 0.30 | 0.01 | 0.03 | 0.08 | 0.17 | 0.08 | 0.08 | 0.07 | 0 |
| Stdev | 0.16 | 0.16 | 0.01 | 0.04 | 0.05 | 0.14 | 0.06 | 0.07 | 0.04 | 0 |
| Prev(%) | 76.35 | 68.24 | 12.16 | 31.76 | 47.97 | 62.84 | 41.22 | 45.27 | 37.16 | 0 |
Human Microbiome Project 16S RefSeq (V1-V3) (Data from healthy subjects. - not published)
No Notes
Human Microbiome Project 16S RefSeq (V3-V5) (Data from healthy subjects. - not published)
No Notes
Dewhirst 35x9 (35 Taxa by 9 Oral Sites. - not published)
No Notes
| SUBP | SUPP | AKE | BMU | HPA | SAL | THR | PTO | TDO | ANA | |
| Avg (%) | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| n | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| 10thp | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 90thp | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stdev | 0.04 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prev(%) | 8.11 | 11.77 | 4.65 | 8.57 | 3.57 | 8.00 | 3.03 | 0 | 0 | 0 |
Human Microbiome Project Metaphlan (Data from healthy subjects. - not published)
No Notes
